Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Miconazole
- Accession Number
- DB01110 (APRD01115)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Description
An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]
- Structure
Structure for DB01110 (Miconazole)
- Synonyms
- 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
- 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
- Daktarin iv
- Miconazole
- Monistat iv (tn)
- Product Ingredients
Ingredient UNII CAS InChI Key Miconazole nitrate VW4H1CYW1K 22832-87-7 MCCACAIVAXEFAL-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Oravig Tablet 50 mg/1 Buccal Praelia Pharmaceuticals Inc 2012-11-01 2015-12-29 US 
Oravig Tablet 50 mg/1 Buccal Midatech Pharma Us, Inc. 2010-04-16 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Miconazole Nitrate Suppository 200 mg/1 Vaginal Actavis Pharma Company 2002-09-03 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 3M Cavilon Antifungal Cream 2 g/1000g Topical 3 M Pharmaceuticals 2010-11-30 Not applicable US 7 Day Vaginal Cream 2 g/100g Topical Cardinal Health 2009-03-16 Not applicable US Aloe Vesta Antifungal Ointment 20 mg/g Topical Convatec Inc. 1997-10-03 Not applicable US Aloe Vesta Clear Antifungal Ointment 2 g/100g Topical Convatec Inc. 2013-12-20 Not applicable US Aloe Vesta Clear Antifungal 141g Ointment 2.82 g/141g Topical Guest Packaging Llc. 2016-06-09 Not applicable US Aloe Vesta Clear Antifungal 56g Ointment 1.12 g/56g Topical Guest Packaging Llc. 2016-06-09 Not applicable US Anti-Fungal Cream .02 g/g Topical Universal Distribution Center LLC 2015-04-15 Not applicable US Antifungal Cream 2 mg/100mL Topical Mc Kesson 2017-05-26 Not applicable US Antifungal Cream 20 mg/g Topical Preferreed Pharmaceuticals Inc. 2016-08-25 Not applicable US Antifungal Cream 20 mg/g Topical Actavis Pharma Company 2007-05-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End DermaSana Miconazole nitrate (200 mg/mg) + Triclosan (30 mg/mg) Cream Topical Omg Medical Group, Llc 2013-02-14 Not applicable US Monicure Combo Miconazole nitrate (2 %) + Fluconazole (150 mg) Capsule; Cream; Kit Oral; Topical Insight Pharmaceuticals 2012-10-25 Not applicable Canada 
Monistat 1 Combination Pack Miconazole nitrate (1200 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1999-02-26 Not applicable Canada Monistat 1 Combination Pack Miconazole nitrate (1200 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1999-02-26 Not applicable Canada Monistat 3 Dual-pak Miconazole nitrate (2 %) + Miconazole nitrate (400 mg) Cream; Insert Topical; Vaginal Insight Pharmaceuticals 1986-12-31 Not applicable Canada Monistat 3 Dual-pak Miconazole nitrate (2 %) + Miconazole nitrate (400 mg) Cream; Insert Topical; Vaginal Insight Pharmaceuticals 1986-12-31 Not applicable Canada Monistat 7 Dual-pak Miconazole nitrate (100 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1994-12-31 Not applicable Canada Monistat 7 Dual-pak Miconazole nitrate (100 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1994-12-31 Not applicable Canada Rash Relief Antifungal Miconazole nitrate (2 g/100g) + Dimethicone (10 g/100g) + Zinc oxide (10 g/100g) Liquid Topical Touchless Care Concepts LLC 2006-06-14 Not applicable US Vusion Miconazole nitrate (2.5 mg/g) + Petrolatum (813.5 mg/g) + Zinc oxide (150 mg/g) Ointment Topical Prestium Pharma, Inc. 2007-05-14 Not applicable US - International/Other Brands
- Daktarin / Decocort / Femizol-M / Gyno-Daktarin / Miconazex / Monistat / Monistat-Derm / Zeasorb-AF / Zimycan
- Categories
- 14-alpha Demethylase Inhibitors
- Anti-Infective Agents
- Antifungal Agents
- Antifungal Agents (Vaginal)
- Antifungals for Dermatological Use
- Antifungals for Topical Use
- Azole Antifungals
- Chemically-Induced Disorders
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2A6 Inhibitors
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2E1 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologicals
- Enzyme Inhibitors
- Hormone Antagonists
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Imidazole and Triazole Derivatives
- Imidazoles
- P-glycoprotein/ABCB1 Inhibitors
- Steroid Synthesis Inhibitors
- UNII
- 7NNO0D7S5M
- CAS number
- 22916-47-8
- Weight
- Average: 416.129
Monoisotopic: 413.986023908 - Chemical Formula
- C18H14Cl4N2O
- InChI Key
- BYBLEWFAAKGYCD-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
- IUPAC Name
- 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
- SMILES
- ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
Pharmacology
- Indication
For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.
- Structured Indications
- Pharmacodynamics
Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.
- Mechanism of action
Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.
- Affected organisms
- Fungi, yeast and protozoans
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Miconazole. Approved, Investigational Acetohexamide Miconazole may increase the hypoglycemic activities of Acetohexamide. Approved, Investigational, Withdrawn Afatinib The serum concentration of Afatinib can be increased when it is combined with Miconazole. Approved Agmatine The therapeutic efficacy of Miconazole can be increased when used in combination with Agmatine. Experimental, Investigational Amiodarone The metabolism of Miconazole can be decreased when combined with Amiodarone. Approved, Investigational Amlodipine The therapeutic efficacy of Miconazole can be increased when used in combination with Amlodipine. Approved Amphotericin B The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole. Approved, Investigational Amrinone The therapeutic efficacy of Miconazole can be increased when used in combination with Amrinone. Approved Apalutamide The serum concentration of Miconazole can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Miconazole can be increased when it is combined with Aprepitant. Approved, Investigational Aranidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Aranidipine. Approved, Investigational Artesunate The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Miconazole resulting in a loss in efficacy. Approved, Investigational Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Miconazole. Approved, Investigational, Withdrawn Atazanavir The metabolism of Miconazole can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Miconazole can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Miconazole is combined with Atorvastatin. Approved Azelnidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Azelnidipine. Approved, Investigational Azimilide The therapeutic efficacy of Miconazole can be increased when used in combination with Azimilide. Investigational Barnidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Barnidipine. Approved Bencyclane The therapeutic efficacy of Miconazole can be increased when used in combination with Bencyclane. Experimental Benidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Benidipine. Approved, Investigational Bepridil The therapeutic efficacy of Miconazole can be increased when used in combination with Bepridil. Approved, Withdrawn Boceprevir The metabolism of Miconazole can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Miconazole can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Miconazole can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Miconazole. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole. Approved, Investigational Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Miconazole. Approved, Investigational Buspirone The metabolism of Buspirone can be decreased when combined with Miconazole. Approved, Investigational Busulfan The serum concentration of Busulfan can be increased when it is combined with Miconazole. Approved, Investigational Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Miconazole. Approved Carbamazepine The metabolism of Miconazole can be increased when combined with Carbamazepine. Approved, Investigational Carboxyamidotriazole The therapeutic efficacy of Miconazole can be increased when used in combination with Carboxyamidotriazole. Investigational Carbutamide Miconazole may increase the hypoglycemic activities of Carbutamide. Experimental Caroverine The therapeutic efficacy of Miconazole can be increased when used in combination with Caroverine. Experimental Ceritinib The serum concentration of Miconazole can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Miconazole. Approved, Withdrawn Chlorpropamide Miconazole may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Cilnidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Cilnidipine. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Miconazole. Approved, Investigational Cinnarizine The therapeutic efficacy of Miconazole can be increased when used in combination with Cinnarizine. Approved, Investigational Cisapride The serum concentration of Cisapride can be increased when it is combined with Miconazole. Approved, Investigational, Withdrawn Clarithromycin The metabolism of Miconazole can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Miconazole can be decreased when combined with Clemastine. Approved, Investigational Clevidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Clevidipine. Approved, Investigational Clorindione The serum concentration of Clorindione can be increased when it is combined with Miconazole. Experimental Clotrimazole The metabolism of Miconazole can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Miconazole can be decreased when combined with Cobicistat. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Miconazole. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Miconazole. Approved, Investigational Crizotinib The metabolism of Miconazole can be decreased when combined with Crizotinib. Approved Cyclandelate The therapeutic efficacy of Miconazole can be increased when used in combination with Cyclandelate. Approved Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole. Approved Dabrafenib The serum concentration of Miconazole can be decreased when it is combined with Dabrafenib. Approved, Investigational Darodipine The therapeutic efficacy of Miconazole can be increased when used in combination with Darodipine. Experimental Darunavir The metabolism of Miconazole can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Miconazole can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Miconazole can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Miconazole can be decreased when combined with Delavirdine. Approved Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Miconazole. Approved Didanosine Didanosine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Miconazole. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Miconazole. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Miconazole. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Miconazole. Approved, Investigational Diltiazem The metabolism of Miconazole can be decreased when combined with Diltiazem. Approved, Investigational Diphenadione The serum concentration of Diphenadione can be increased when it is combined with Miconazole. Experimental Docetaxel The metabolism of Docetaxel can be decreased when combined with Miconazole. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Miconazole. Approved, Investigational Dotarizine The therapeutic efficacy of Miconazole can be increased when used in combination with Dotarizine. Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Miconazole. Approved, Investigational Doxycycline The metabolism of Miconazole can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Miconazole can be decreased when combined with Dronedarone. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Miconazole. Approved Efonidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Efonidipine. Approved, Investigational Enzalutamide The serum concentration of Miconazole can be decreased when it is combined with Enzalutamide. Approved Eperisone The therapeutic efficacy of Miconazole can be increased when used in combination with Eperisone. Approved, Investigational Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Miconazole. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Miconazole. Approved Erythromycin The metabolism of Miconazole can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Ethosuximide The therapeutic efficacy of Miconazole can be increased when used in combination with Ethosuximide. Approved Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole. Withdrawn Etravirine The serum concentration of Etravirine can be increased when it is combined with Miconazole. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Miconazole. Approved Felodipine The therapeutic efficacy of Miconazole can be increased when used in combination with Felodipine. Approved, Investigational Fendiline The therapeutic efficacy of Miconazole can be increased when used in combination with Fendiline. Withdrawn Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole. Approved Fluconazole The metabolism of Miconazole can be decreased when combined with Fluconazole. Approved, Investigational Fluindione The serum concentration of Fluindione can be increased when it is combined with Miconazole. Approved, Investigational Flunarizine The therapeutic efficacy of Miconazole can be increased when used in combination with Flunarizine. Approved Fluspirilene The therapeutic efficacy of Miconazole can be increased when used in combination with Fluspirilene. Approved, Investigational Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Miconazole. Approved Fluvoxamine The metabolism of Miconazole can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Miconazole can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Miconazole can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Miconazole. Approved, Investigational Fusidic Acid The serum concentration of Miconazole can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The therapeutic efficacy of Miconazole can be increased when used in combination with Gabapentin. Approved, Investigational Gallopamil The therapeutic efficacy of Miconazole can be increased when used in combination with Gallopamil. Investigational Glibornuride Miconazole may increase the hypoglycemic activities of Glibornuride. Investigational, Withdrawn Gliclazide Miconazole may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Miconazole may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Miconazole may increase the hypoglycemic activities of Glipizide. Approved, Investigational Gliquidone Miconazole may increase the hypoglycemic activities of Gliquidone. Approved, Investigational Glisoxepide Miconazole may increase the hypoglycemic activities of Glisoxepide. Investigational Glyburide Miconazole may increase the hypoglycemic activities of Glyburide. Approved Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Miconazole. Approved Idelalisib The metabolism of Miconazole can be decreased when combined with Idelalisib. Approved Imatinib The metabolism of Miconazole can be decreased when combined with Imatinib. Approved Indinavir The metabolism of Miconazole can be decreased when combined with Indinavir. Approved Isavuconazole The serum concentration of Miconazole can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Miconazole can be decreased when combined with Isavuconazonium. Approved, Investigational Isradipine The metabolism of Miconazole can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Miconazole can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Miconazole can be increased when it is combined with Ivacaftor. Approved Ketoconazole The metabolism of Miconazole can be decreased when combined with Ketoconazole. Approved, Investigational Lacidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Lacidipine. Approved, Investigational Lamotrigine The therapeutic efficacy of Miconazole can be increased when used in combination with Lamotrigine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Miconazole. Approved Lercanidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Lercanidipine. Approved, Investigational Levetiracetam The therapeutic efficacy of Miconazole can be increased when used in combination with Levetiracetam. Approved, Investigational Lidoflazine The therapeutic efficacy of Miconazole can be increased when used in combination with Lidoflazine. Experimental Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Miconazole. Approved, Investigational Loperamide The therapeutic efficacy of Miconazole can be increased when used in combination with Loperamide. Approved Lopinavir The metabolism of Miconazole can be decreased when combined with Lopinavir. Approved Lorpiprazole The serum concentration of Miconazole can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Losartan can be decreased when combined with Miconazole. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Miconazole. Approved, Investigational Luliconazole The serum concentration of Miconazole can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Miconazole can be increased when combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Miconazole. Illicit, Investigational, Withdrawn Magnesium sulfate The therapeutic efficacy of Miconazole can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The therapeutic efficacy of Miconazole can be increased when used in combination with Manidipine. Approved, Investigational Metahexamide Miconazole may increase the hypoglycemic activities of Metahexamide. Experimental Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Miconazole. Experimental Methsuximide The therapeutic efficacy of Miconazole can be increased when used in combination with Methsuximide. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Miconazole. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Miconazole. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Miconazole. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Miconazole. Experimental Mibefradil The therapeutic efficacy of Miconazole can be increased when used in combination with Mibefradil. Investigational, Withdrawn Mifepristone The serum concentration of Miconazole can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Miconazole can be decreased when it is combined with Mitotane. Approved Naftopidil The therapeutic efficacy of Miconazole can be increased when used in combination with Naftopidil. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Miconazole. Approved Nefazodone The metabolism of Miconazole can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Miconazole can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Miconazole can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Miconazole can be increased when combined with Nevirapine. Approved Nicardipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Miconazole. Approved, Investigational Nifedipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nifedipine. Approved Niguldipine The therapeutic efficacy of Miconazole can be increased when used in combination with Niguldipine. Experimental Nilotinib The metabolism of Miconazole can be decreased when combined with Nilotinib. Approved, Investigational Niludipine The therapeutic efficacy of Miconazole can be increased when used in combination with Niludipine. Experimental Nilvadipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Miconazole can be increased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nimodipine. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Miconazole. Approved Nisoldipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nisoldipine. Approved Nitrendipine The therapeutic efficacy of Miconazole can be increased when used in combination with Nitrendipine. Approved, Investigational Olaparib The metabolism of Miconazole can be decreased when combined with Olaparib. Approved Osimertinib The serum concentration of Miconazole can be increased when it is combined with Osimertinib. Approved Otilonium The therapeutic efficacy of Miconazole can be increased when used in combination with Otilonium. Experimental, Investigational Palbociclib The serum concentration of Miconazole can be increased when it is combined with Palbociclib. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Miconazole. Approved Pentobarbital The metabolism of Miconazole can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Miconazole. Approved, Investigational, Vet Approved, Withdrawn Phenindione The serum concentration of Phenindione can be increased when it is combined with Miconazole. Approved, Investigational Phenobarbital The metabolism of Miconazole can be increased when combined with Phenobarbital. Approved, Investigational Phenprocoumon The serum concentration of Phenprocoumon can be increased when it is combined with Miconazole. Approved, Investigational Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Miconazole. Approved, Vet Approved Pinaverium The therapeutic efficacy of Miconazole can be increased when used in combination with Pinaverium. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Miconazole. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Miconazole. Approved, Investigational Posaconazole The metabolism of Miconazole can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Miconazole. Approved Prenylamine The therapeutic efficacy of Miconazole can be increased when used in combination with Prenylamine. Withdrawn Primidone The metabolism of Miconazole can be increased when combined with Primidone. Approved, Vet Approved Progesterone The absorption of Progesterone can be decreased when combined with Miconazole. Approved, Vet Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Miconazole. Approved Quinidine The serum concentration of Quinidine can be increased when it is combined with Miconazole. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Miconazole. Approved, Investigational Rifabutin The metabolism of Miconazole can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Miconazole can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Miconazole can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Miconazole. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Miconazole. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Miconazole. Approved Rucaparib The metabolism of Miconazole can be decreased when combined with Rucaparib. Approved, Investigational Saquinavir The metabolism of Miconazole can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Miconazole can be decreased when used in combination with Sarilumab. Approved, Investigational Seletracetam The therapeutic efficacy of Miconazole can be increased when used in combination with Seletracetam. Investigational Sildenafil The metabolism of Miconazole can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Miconazole. Approved Siltuximab The serum concentration of Miconazole can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Miconazole can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Miconazole. Approved Solifenacin The metabolism of Solifenacin can be decreased when combined with Miconazole. Approved St. John's Wort The serum concentration of Miconazole can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Miconazole can be increased when it is combined with Stiripentol. Approved Sucralfate Sucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sulfisoxazole The metabolism of Miconazole can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sunitinib The metabolism of Sunitinib can be decreased when combined with Miconazole. Approved, Investigational Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Miconazole. Approved, Investigational Telaprevir The metabolism of Miconazole can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Miconazole can be decreased when combined with Telithromycin. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Miconazole. Experimental Terodiline The therapeutic efficacy of Miconazole can be increased when used in combination with Terodiline. Experimental Tetrahydropalmatine The therapeutic efficacy of Miconazole can be increased when used in combination with Tetrahydropalmatine. Investigational Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Miconazole. Approved, Withdrawn Ticlopidine The metabolism of Miconazole can be decreased when combined with Ticlopidine. Approved Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with Miconazole. Experimental Tocilizumab The serum concentration of Miconazole can be decreased when it is combined with Tocilizumab. Approved Tolazamide Miconazole may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Miconazole may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid The therapeutic efficacy of Miconazole can be increased when used in combination with Tolfenamic Acid. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Miconazole. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Miconazole. Approved, Investigational Tranilast The therapeutic efficacy of Miconazole can be increased when used in combination with Tranilast. Approved, Investigational Trimebutine The therapeutic efficacy of Miconazole can be increased when used in combination with Trimebutine. Approved Trimethadione The therapeutic efficacy of Miconazole can be increased when used in combination with Trimethadione. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Miconazole. Approved Venlafaxine The metabolism of Miconazole can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Miconazole can be decreased when combined with Verapamil. Approved Vincristine The excretion of Vincristine can be decreased when combined with Miconazole. Approved, Investigational Vinpocetine The therapeutic efficacy of Miconazole can be increased when used in combination with Vinpocetine. Investigational Voriconazole The metabolism of Miconazole can be decreased when combined with Voriconazole. Approved, Investigational Warfarin The serum concentration of Warfarin can be increased when it is combined with Miconazole. Approved WIN 55212-2 The therapeutic efficacy of Miconazole can be increased when used in combination with WIN 55212-2. Experimental Ziconotide The therapeutic efficacy of Miconazole can be increased when used in combination with Ziconotide. Approved Ziprasidone The metabolism of Miconazole can be decreased when combined with Ziprasidone. Approved Zolpidem The serum concentration of Zolpidem can be increased when it is combined with Miconazole. Approved Zonisamide The therapeutic efficacy of Miconazole can be increased when used in combination with Zonisamide. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
- US3717655
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015242
- KEGG Drug
- D00882
- KEGG Compound
- C08070
- PubChem Compound
- 4189
- PubChem Substance
- 46506017
- ChemSpider
- 4044
- BindingDB
- 31772
- ChEBI
- 82892
- ChEMBL
- CHEMBL91
- Therapeutic Targets Database
- DAP000154
- PharmGKB
- PA450494
- IUPHAR
- 2449
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Miconazole
- ATC Codes
- A01AB09 — Miconazole
- A01AB — Antiinfectives and antiseptics for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- D01AC — Imidazole and triazole derivatives
- D01A — ANTIFUNGALS FOR TOPICAL USE
- D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE
- D — DERMATOLOGICALS
- J02AB — Imidazole derivatives
- J02A — ANTIMYCOTICS FOR SYSTEMIC USE
- J02 — ANTIMYCOTICS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- A07AC — Imidazole derivatives
- A07A — INTESTINAL ANTIINFECTIVES
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- G01AF — Imidazole derivatives
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- AHFS Codes
- 84:04.08.08 — Azoles
- FDA label
- Download (650 KB)
- MSDS
- Download (73.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Barr Pharmaceuticals
- CVS Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Draxis Specialty Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Johnson & Johnson Healthcare
- Kaiser Foundation Hospital
- Medisca Inc.
- Ortho Mcneil Janssen Pharmaceutical Inc.
- Orthopedics Advanced Care
- Par Pharmaceuticals
- Perrigo Co.
- Pharmacia Inc.
- Pharmedix
- Physicians Total Care Inc.
- Prescript Pharmaceuticals
- Schering-Plough Inc.
- Southwood Pharmaceuticals
- Dosage forms
Form Route Strength Ointment Topical 20 mg/g Ointment Topical 2.82 g/141g Ointment Topical 1.12 g/56g Cream Topical 2 mg/100mL Cream Topical 2 g/1000g Powder Topical 2 g/100mL Tincture Topical 20 mg/mL Cream Topical .02 g/g Spray Topical 20 mg/g Cream Topical .02 g/100g Cream Topical Cream Topical 20 g/1000g Spray Topical 2 g/100g Cream Topical 2 g/100g Cream Topical 20 mg/mL Aerosol, spray Topical .2 g/10g Cream Topical 20 mg/g Powder Topical 1.42 g/71g Aerosol, powder Topical 20 mg/g Liquid Topical 2 g/100g Cream Topical 2 % Aerosol Topical 2 % Kit Topical; Vaginal Kit Vaginal Suppository Vaginal 400 mg Cream Vaginal 2 mg/100g Cream Vaginal 2 g/100g Cream Vaginal 20 mg/100g Suppository Vaginal 100 mg/1 Aerosol, powder Topical 2.6 g/130g Aerosol, spray Topical 1.3 g/131g Aerosol, spray Topical 1.3 g/130g Aerosol, spray Topical 2 g/150g Aerosol, spray Topical 2.6 g/130g Aerosol, spray Topical 3 g/150g Cream Vaginal 20 mg/g Powder Topical 2.6 g/130g Spray Topical 3 g/150g Suppository Vaginal 100 ug/1 Suppository Vaginal 200 mg/1 Powder Topical 20 mg/g Cream Topical .3 g/14g Cream Vaginal 20 mg Capsule; cream; kit Oral; Topical Suppository Vaginal 1200 mg Cream; insert Topical; Vaginal Cream Vaginal 4 % Insert Vaginal 400 mg Cream; suppository Topical; Vaginal Suppository Vaginal 100 mg Cream Vaginal 2 % Cream Topical 200 mg/mg Cream Topical .02 mL/mL Tablet Buccal 50 mg/1 Liquid Topical Powder Topical 2 g/100g Cream Topical 20 mg/100g Kit Cream Topical .7 g/35g Aerosol, powder Topical 2.56 g/128g Cream Vaginal 40 mg/g Liquid Topical .3 mg/15mL Ointment Topical Ointment Topical 2 g/100g Powder Topical 20.6 mg/g - Prices
Unit description Cost Unit Vusion 0.25-15-81.35% Ointment 50 gm Tube 284.34USD tube Miconazole 3 3 200 mg Suppository Box 51.2USD box Monistat-Derm 2% Cream 28.35 gm Tube 41.99USD tube Monistat-Derm 2% Cream 15 gm Tube 32.0USD tube Monistat 1 combination pack 16.81USD each Monistat 7 combination pack 15.96USD each Miconazole Nitrate 2% Cream 28 gm Tube 12.99USD tube Miconazole powder 4.59USD g Monistat 1 6.5% ointment 3.6USD g Miconazole nitrate powder 3.55USD g Vusion ointment 3.17USD g Monistat-derm 2% cream 1.11USD g Miconazole nitrate 2% cream 0.19USD g CVS Pharmacy miconazole 7 cream 0.18USD g Miconazole 7 cream 0.15USD g Antifungal 2% cream 0.1USD g Micatin 2% aerosol spray 0.05USD g Lotrimin af 2% liquid spray 0.04USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5514698 No 1994-03-21 2014-03-21 US US8147852 No 2008-03-30 2028-03-30 US US6153635 No 2000-11-28 2020-11-28 US US6916485 No 2002-09-11 2022-09-11 US US7651698 No 2002-09-11 2022-09-11 US US8518442 No 2002-09-11 2022-09-11 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 159-163 °C Not Available water solubility 1g/100mL (20 °C) Not Available logP 6.1 Not Available - Predicted Properties
Property Value Source Water Solubility 0.000763 mg/mL ALOGPS logP 5.86 ALOGPS logP 5.96 ChemAxon logS -5.7 ALOGPS pKa (Strongest Basic) 6.77 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 27.05 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 103.07 m3·mol-1 ChemAxon Polarizability 39.54 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9735 Blood Brain Barrier + 0.9823 Caco-2 permeable + 0.6096 P-glycoprotein substrate Non-substrate 0.545 P-glycoprotein inhibitor I Non-inhibitor 0.7958 P-glycoprotein inhibitor II Inhibitor 0.8387 Renal organic cation transporter Inhibitor 0.6806 CYP450 2C9 substrate Non-substrate 0.8407 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.7017 CYP450 1A2 substrate Inhibitor 0.9472 CYP450 2C9 inhibitor Inhibitor 0.939 CYP450 2D6 inhibitor Inhibitor 0.9413 CYP450 2C19 inhibitor Inhibitor 0.9591 CYP450 3A4 inhibitor Inhibitor 0.8861 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9961 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.853 Biodegradation Not ready biodegradable 0.9933 Rat acute toxicity 2.8478 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5 hERG inhibition (predictor II) Inhibitor 0.8505
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzylethers
- Direct Parent
- Benzylethers
- Alternative Parents
- Dichlorobenzenes / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Benzylether / 1,3-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / N-substituted imidazole / Imidazole / Azole / Heteroaromatic compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- imidazoles, ether, dichlorobenzene (CHEBI:82892) / a small molecule (CPD-4501)
Targets
- Kind
- Protein
- Organism
- Yeast
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sterol 14-demethylase activity
- Specific Function
- Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
- Gene Name
- ERG11
- Uniprot ID
- P10613
- Uniprot Name
- Lanosterol 14-alpha demethylase
- Molecular Weight
- 60674.965 Da
References
- White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998 Apr;11(2):382-402. [PubMed:9564569]
- Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17. [PubMed:10515900]
- Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848]
- Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996 Feb;40(2):279-91. [PubMed:8834867]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tetrahydrobiopterin binding
- Specific Function
- Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
- Gene Name
- NOS3
- Uniprot ID
- P29474
- Uniprot Name
- Nitric oxide synthase, endothelial
- Molecular Weight
- 133287.62 Da
References
- Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
- Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
- Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
- Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tetrahydrobiopterin binding
- Specific Function
- Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
- Gene Name
- NOS2
- Uniprot ID
- P35228
- Uniprot Name
- Nitric oxide synthase, inducible
- Molecular Weight
- 131116.3 Da
References
- Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
- Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
- Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
- Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
- Gene Name
- KCNMA1
- Uniprot ID
- Q12791
- Uniprot Name
- Calcium-activated potassium channel subunit alpha-1
- Molecular Weight
- 137558.115 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Incr...
- Gene Name
- KCNMB1
- Uniprot ID
- Q16558
- Uniprot Name
- Calcium-activated potassium channel subunit beta-1
- Molecular Weight
- 21797.27 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Acts...
- Gene Name
- KCNMB2
- Uniprot ID
- Q9Y691
- Uniprot Name
- Calcium-activated potassium channel subunit beta-2
- Molecular Weight
- 27129.37 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Alte...
- Gene Name
- KCNMB3
- Uniprot ID
- Q9NPA1
- Uniprot Name
- Calcium-activated potassium channel subunit beta-3
- Molecular Weight
- 31603.26 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Decr...
- Gene Name
- KCNMB4
- Uniprot ID
- Q86W47
- Uniprot Name
- Calcium-activated potassium channel subunit beta-4
- Molecular Weight
- 23948.465 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein phosphatase binding
- Specific Function
- Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Requi...
- Gene Name
- KCNN4
- Uniprot ID
- O15554
- Uniprot Name
- Intermediate conductance calcium-activated potassium channel protein 4
- Molecular Weight
- 47695.12 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN1
- Uniprot ID
- Q92952
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 1
- Molecular Weight
- 59986.87 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN2
- Uniprot ID
- Q9H2S1
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 2
- Molecular Weight
- 63759.03 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN3
- Uniprot ID
- Q9UGI6
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 3
- Molecular Weight
- 82025.305 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
- Gene Name
- KCNH2
- Uniprot ID
- Q12809
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 2
- Molecular Weight
- 126653.52 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
- Gene Name
- KCNH6
- Uniprot ID
- Q9H252
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 6
- Molecular Weight
- 109923.705 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
- Gene Name
- KCNH7
- Uniprot ID
- Q9NS40
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 7
- Molecular Weight
- 134998.525 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Partial agonist
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
- Gene Name
- NR1I2
- Uniprot ID
- O75469
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 2
- Molecular Weight
- 49761.245 Da
References
- Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12. [PubMed:17998298]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid 11-beta-monooxygenase activity
- Specific Function
- Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
- Gene Name
- CYP11B1
- Uniprot ID
- P15538
- Uniprot Name
- Cytochrome P450 11B1, mitochondrial
- Molecular Weight
- 57572.44 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
- Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:04